Medtronic launches new diabetes system
Medtronic launched Paradigm Veo system, a new diabetes device that can suspend insulin delivery when it senses that glucose levels have fallen to or below a user-selected threshold, at the International Society for Pediatric and Adolescent Diabetes in Ljubljana, Slovenia, Sept. 2-5.
The device is intended to reduce the severity of hypoglycemia in situations where patients ignore or are unable to treat hypoglycemia, according to the Minneapolis-based company. If left untreated, hypoglycemia can cause loss of consciousness, seizure, coma or even death.
Paradigm Veo includes an insulin pump with a continuous glucose monitoring system (provided by means of a separate sensor and transmitter). The patient uses readings from the monitor in conjunction with occasional confirmatory fingerstick blood glucose measurements to understand their current glucose level. Based on these results, the patient then programs the insulin pump to deliver an appropriate amount of insulin.
The device is intended to reduce the severity of hypoglycemia in situations where patients ignore or are unable to treat hypoglycemia, according to the Minneapolis-based company. If left untreated, hypoglycemia can cause loss of consciousness, seizure, coma or even death.
Paradigm Veo includes an insulin pump with a continuous glucose monitoring system (provided by means of a separate sensor and transmitter). The patient uses readings from the monitor in conjunction with occasional confirmatory fingerstick blood glucose measurements to understand their current glucose level. Based on these results, the patient then programs the insulin pump to deliver an appropriate amount of insulin.